Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Evaluation of Neoadjuvant Therapy Response of Osteogenic Sarcoma Using FDG PET

Michael Schulte, Doris Brecht-Krauss, Mathias Werner, Erich Hartwig, Michael R. Sarkar, Peter Keppler, Jörg Kotzerke, Albrecht Guhlmann, Günter Delling and Sven N. Reske
Journal of Nuclear Medicine October 1999, 40 (10) 1637-1643;
Michael Schulte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doris Brecht-Krauss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Werner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erich Hartwig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Sarkar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Keppler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörg Kotzerke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albrecht Guhlmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Günter Delling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven N. Reske
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 40, Issue 10
October 1, 1999
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Neoadjuvant Therapy Response of Osteogenic Sarcoma Using FDG PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of Neoadjuvant Therapy Response of Osteogenic Sarcoma Using FDG PET
Michael Schulte, Doris Brecht-Krauss, Mathias Werner, Erich Hartwig, Michael R. Sarkar, Peter Keppler, Jörg Kotzerke, Albrecht Guhlmann, Günter Delling, Sven N. Reske
Journal of Nuclear Medicine Oct 1999, 40 (10) 1637-1643;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of Neoadjuvant Therapy Response of Osteogenic Sarcoma Using FDG PET
Michael Schulte, Doris Brecht-Krauss, Mathias Werner, Erich Hartwig, Michael R. Sarkar, Peter Keppler, Jörg Kotzerke, Albrecht Guhlmann, Günter Delling, Sven N. Reske
Journal of Nuclear Medicine Oct 1999, 40 (10) 1637-1643;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 18F-FDG PET/CT in the Management of Osteosarcoma
  • 18F-FDG PET/CT in the Management of Osteosarcoma
  • Combination of 18F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma
  • Imaging features of primary and secondary malignant tumours of the sacrum
  • Imaging in Sarcoma
  • Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis
  • Prediction Model of Chemotherapy Response in Osteosarcoma by 18F-FDG PET and MRI
  • Measuring Response with FDG-PET: Methodological Aspects
  • 18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma
  • Controversies in the Management of Oropharynx Cancer
  • Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
  • PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
  • Ewing's Sarcoma Family of Tumors: Current Management.
  • PET for response assessment in oncology: radiotherapy and chemotherapy
  • Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
  • Biology and Therapeutic Advances for Pediatric Osteosarcoma
  • Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
  • PET Imaging of Osteosarcoma
  • Prognostic Significance of 18F-FDG and 99mTc-Methylene Diphosphonate Uptake in Primary Osteosarcoma
  • Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas
  • Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET
  • Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire